You can now read 10 articles a month for free. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

6

2

Final

Inspiration Biopharmaceuticals, Ipsen to sell hemophilia drug candidate

Inspiration Biopharmaceuticals, a Cambridge biopharmaceutical company focused on hemophilia, and Ipsen said Thursday that they have agreed to sell a hemophilia drug candidate to Baxter International Inc., a large Illinois-based health care company with specialties in medical devices, pharmaceuticals and biotechnology.

Baxter has agreed to make an upfront payment of $50 million as well as milestone payments totaling $135 million. Inspiration and Ipsen are also eligible to receive annual net sales payments equivalent to a tiered double digit percentage of global net sales. As a result, the aggregate purchase price could exceed $700 million, Inspiration and Ipsen said in a press release.

Continue reading below

As part of the deal, Baxter will acquire the worldwide rights to OBI-1, a recombinant porcine factor VIII in development for congenital hemophilia A with inhibitors and acquired hemophilia A. Baxter will also acquire Ipsen’s manufacturing facility for OBI-1 in Milford.

Inspiration filed for Chapter 11 bankruptcy protection in October and is in the process of selling off its assets, a company spokesman said.

“Inspiration was founded by families who are personally affected by hemophilia, so bringing innovative therapies to patients has always been at the core of our mission” John P. Butler, Inspiration’s chief executive, said in a statement. “Baxter has a long commitment to hemophilia and we are excited that they will be using their expertise to bring this innovative therapy to people who currently have limited treatment options.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week